CAS: 952-54-5; Morinamide

📜吡嗪酰胺 以 丙酮,甲苯 作为反应溶剂,化学反应 20.0H,反应生成 吗啉米特
参考文献:Synthesis And Antimycobacterial Activity Of Some New Pyrazinamide Derivatives
标题:Synthesis And Antimycobacterial Activity Of Some New Pyrazinamide Derivatives
摘要:一些吡嗪酰胺衍生物(2A-2E,2A'-2E'和2A''-2E'')被合成并作为抗结核分枝杆菌h37Rv菌株的抗分枝杆菌药物进行了评估.这些衍生物是通过分别用烷基链和六元杂环对吡嗪酰胺进行结构修饰而设计的.标题化合物以吡嗪酰胺为起始原料,通过卤代烷基化反应(1A-1C)合成,然后将卤代烷基吡嗪酰胺与适当的杂环反应.化合物的结构通过1H NMR,13C NMR,质谱和元素分析进行了确认.吡嗪酰胺衍生物的活性通过微孔板alamar Blue检测(maba)进行了测定,并通过最小抑菌浓度(mic)进行了表征.结果表明,所获得的吡嗪酰胺衍生物对结核分枝杆菌具有很高的抑制作用.在测试的所有化合物中,化合物2B',2D'和2E'的抗分枝杆菌活性最好,其mic值约为6.25 Mμ/ml.这些化合物在吡嗪酰胺部分和六元杂环之间具有乙烯链.
DOI:10.1007/s11094-022-02662-7

专利信息

专利号:US-12391691-B2
优先权日:2018-11-16
标题:Synthesis of key intermediate of KRAS G12C inhibitor compound
发明人：PARSONS ANDREW THOMAS; COCHRAN BRIAN MCNEIL; POWAZINIK IV WILLIAM; CAPORINI MARC ANTHONY
权利人:AMGEN INC
摘要:The present invention relates to an improved, efficient, scalable process to prepare intermediate compounds, such as compound 5M, having the structure n nuseful for the synthesis of compounds that target KRAS G12C mutations, such as

专利号:US-2025206736-A1
优先权日:2019-11-14
标题 :Synthesis of kras g12c inhibitor compound
发明人：CORBETT MICHAEL THOMAS; CAILLE SEBASTIEN
权利人:AMGEN INC
摘要:The present disclosure relates to an improved, efficient, scalable process to prepare intermediate compounds, such as 2-isopropyl-4-methylpyridin-3-amine, useful for the synthesis of compounds, such as Compound 9, for the treatment of KRAS G12C mutated cancers.

专利号:US-2023192681-A1
优先权日:2019-11-14
标 题 :Improved synthesis of kras g12c inhibitor compound

专利号:US-7989004-B2
优先权日:2004-05-27
标题:Antitubercular extracts of Salicornia brachiata
发明人：RATHOD MEENA RAJNIKANT; SHETHIA BHUPENDRA DHANVANTRAI; PANDYA JAYANT BATUKRAL; GHOSH PUSHPITO KUMAR; DODIA PRAKASH JAGIVANBHAL; SRIVASTAVA BRAHM S; SRIVASTAVA RANJANA; SRIVASTAVA ANIL; CHATURVEDI VINITA; VAIRAMANI MARIAPPANADAR
权利人:COUNCIL SCIENT IND RES
摘要:The present invention relates to enhancement of anti-tubercular activity of active fraction isolated from Salicornia brachiata . The invention also discloses the non-toxic nature of the fraction and positively identifies Sucrose as its main constituent. Pure Sucrose is shown to have no anti-tubercular activity indicating thereby that activity of the fraction resides in one or more of the minor constituents. The minor constituents are shown to be relatively low molecular weight entities and a chromatographic technique is disclosed for separating them from the bulk sucrose to probe their activities and structures in detail, as also the possibility of their synthesis if the leads thrown up are novel.

专利号:US-11299491-B2
优先权日:2018-11-16
标 题:Synthesis of key intermediate of KRAS G12C inhibitor compound

专利号:US-2025206735-A1
优先权日:2018-11-16
标题:Synthesis of key intermediate of kras g12c inhibitor compound